Data Year:

For its 2024 fiscal year, ROCKET PHARMACEUTICALS, INC., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Gaurav D. Shah M.D.
Chief Executive Officer
Total Compensation $6,841,407 View details Pay Rank By Title In Biotechnology industry #185 View more
Jonathan Schwartz M.D.
Chief Medical and Gene Therapy Officer
Total Compensation $2,364,309 View details Pay Rank By Title In Biotechnology industry #154 View more
Kinnari Patel Pharm.D., MBA
President, Head of R&D and Chief Operating Officer
Total Compensation $6,696,056 View details Pay Rank By Title In Biotechnology industry #11 View more
John Militello
Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President
Total Compensation $1,175,588 View details Pay Rank By Title In Biotechnology industry #16 View more
Martin Wilson J.D.
General Counsel and Chief Corporate Officer, Senior VP
Total Compensation $2,113,954 View details Pay Rank By Title In Biotechnology industry #29 View more
Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Total Compensation $2,989,763 View details Pay Rank By Title In Biotechnology industry #152 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at ROCKET PHARMACEUTICALS, INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ROCKET PHARMACEUTICALS, INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ROCKET PHARMACEUTICALS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Gaurav D. Shah M.D.
Chief Executive Officer
Total Cash $826,644 Equity $5,999,973 Other $14,790 $6,841,407
Jonathan Schwartz M.D.
Chief Medical and Gene Therapy Officer
Total Cash $599,544 Equity $1,749,975 Other $14,790 $2,364,309
Kinnari Patel Pharm.D., MBA
President, Head of R&D and Chief Operating Officer
Total Cash $681,300 Equity $5,999,966 Other $14,790 $6,696,056
John Militello
Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President
Total Cash $410,660 Equity $749,977 Other $14,951 $1,175,588
Martin Wilson J.D.
General Counsel and Chief Corporate Officer, Senior VP
Total Cash $599,189 Equity $1,499,975 Other $14,790 $2,113,954
Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Total Cash $480,164 Equity $2,499,971 Other $9,628 $2,989,763
For its 2024 fiscal year, ROCKET PHARMACEUTICALS, INC., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Gaurav D. Shah M.D. CEO Pay $6,841,407 Median Employee Pay $138,170 CEO Pay Ratio 50:1
For its 2024 fiscal year, ROCKET PHARMACEUTICALS, INC., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Carsten Boess Total Cash $429,467
David Southwell Total Cash $404,610
Elisabeth Björk, M.D., Ph.D. Total Cash $416,926
Fady Malik, M.D., Ph.D. Total Cash $401,967
Gotham Makker, M.D. Total Cash $405,783
Keith Woods Total Cash $413,944
Mikael Dolsten, M.D., Ph.D. Total Cash $669,251
Naveen Yamalanchi Total Cash $410,547
Pedro Granadillo Total Cash $429,977
Roderick Wong, M.D. Total Cash $409,981
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.